When James Norris, a 56-year-old mechanic from Roxbaster, New Jersey, a low dose of Monjo, a GLP-1-like drug, to lose weight in March 2023, was believed to be a miracle drug.
In 289 pounds, he was fighting to lose weight for years with diet and exercise. His wife lost 60 lbs in several months on the medicine, and convinced him of her success by giving him a bullet.
“I couldn't maintain weight – [the drug] It looked like a good alternative. “
In the year after this, 89 lbs and managed to dismantle the medications he was taking for high blood pressure and cholesterol.
Then, in March 2024, shortly after his doctor raised his dose to 2.5 milligrams (he started at 1.5 mg), he woke up one morning with a cloudy vision in his left eye. After two weeks, the vision in its right eye became blurry.
“I did not know what was going on,” said Norris, who initially believed that sinus infection might be responsible.
However, after obtaining a CT scanning and seeing a nervous ophthalmologist, it was revealed that he suffers from non -Sharif's anterior optical neuropathy (NAION), a condition in which the loss of blood flow to the optic nerve leads to sudden vision loss.
He said, “I have been destroyed.” “It is extremely rare to get Nayon in both eyes.”
Recent studies have shown a relationship between medicines such as OzemPIC, Mountrao and Wegovy – which has become tremendously common to weight loss – and increased NAION.
Of the 15 million Americans, they are now taking such medications for type 2 diabetes and weight loss, only a few relatively few are facing this problem, but for those who have life change.
“I was a mechanic all my life – I can't do anything anymore,” said Norris, who stopped taking Mountjaro in about July 2024.
It is now working mostly from an administrative work from a computer and believes that the risk of medications, especially in higher doses, is not worth it.
Although it is not clear that the number of people suffering from these drugs with vision problems, Norus's lawyer, Robert King, said that his company alone had received “hundreds” of GLP-1 cases.
“The largest thing is the huge number of eyes infected with something that is supposed to be intestinal medications and the fact that no one doubts that the weight loss drug will make it blind immediately in one eye,” said King, who is based in Rochester, New York.
A review by doctors from doctors from the Eye Center at the University of Utah, which was published in Ophthalmology in Gama on January 30, 2025, looked at nine patients who reported visual loss after taking the pillar or Terzopatid, which are the active ingredients in Ozzbich, Wigofi, Montaru and Zipond.
They found that patients who take these medications have developed three potential blinds that affect the optic nerve – the part of the eye that sends visual signals to the brain.
Of the nine patients, seven NAIOH -like symptoms mentioned; One had papillitis, optic nerve head inflammation. One individual developed a central central cord impurity, which could cause a blind spot vision.
The January study came in the aftermath of the Mass and Ear, an educational hospital at Harvard University College. I found a link between semaglutides and an increase in a risk of NAION.
Diabetics who take the medicine are found to be four times more at risk of Nwin than those who are not on medications. Those with weight gain or obesity and the drug for weight loss were more than seven times in danger.
Norris was not aware of this risk when he went to the medicine.
“I had no idea that this could happen,” he said, noting that he was planning to file a lawsuit against Mountjaro Drugmaker Lilly and Company.
Ozmpic and Mountaro menu “Revelation changes” as a possible side effect on their websites, while wegovy lists the change in vision in people with type 2 diabetes. None of the websites explicitly warn users of Naion.
“The safety of patients is” a top priority “and is” actively involved in monitoring, evaluating and reporting safety information for all our drugs. “
“The Post is a very rare illness, which is not a harmful drug reaction,” said a spokesman for the Novo Nordisk, the Danish manufacturer of Ozmpic and Wegovy. They said that after evaluating the research and evaluating internal safety, “Novo Nordisek believes that the lateral appearance of the risks of the RRIGOLTide is still unchanged.”
Dr. Joseph Rayso, a professor of ophthalmology at the Harvard Medical College and a great author in the study published in ophthalmology in ophthalmology, told the Post newspaper that people do not inhibit these drugs, but those who suffer from visual loss should go with caution.
“Let's say that they do not suffer from diabetes, but they have an advanced glaucoma, then I will be exceptionally eager to take the medicine – you do not start from a natural visual condition.”
Michael Sabeliko, 60, was taking 60 -year -old San Diego, had a natural vision when he went to OzemPic in March 2024 for weight loss and type 2 diabetes management.
When he started, he weighs 185 lbs and was near an ideal vision. Eight weeks after a dose of 1.5 mg, five pounds decreased. But after that he woke up one morning and was not able to see clearly.
The optical specialist found that his optical nerve was inflamed and was diagnosed with NAION. He got steroid to help inflammation.
However, due to the lack of research as NAION is connected to the GLP-1S, doctors also increased his dose of OzemPic to manage blood sugar.
Ozmpic did not stop until May, 2024, and then his vision was permanently weak.
He now has a vision 20/70 in his left eye and less than 20/30 vision in his right eye.
“If I have a patch on my right eyes, it will be difficult to read,” said Sabeliko, who now runs diabetes with drug drugs and plans to take legal measures. “The letters jump.”
Sherrill Buffy, a 56-year-old former retail worker from Winston-Salem, North Carolina, has legal measures against Novo Nordisk. A lawsuit was filed in February that the company's marketing was “deceptive and misleading about the real risks associated with the associated risks [the] Use OzemPic. “
It is lawful after developing NAION while using OzemPic as directed by its doctors to manage type 2 diabetes last year. She was not on the medicine for weight loss, and it is not clear how much weight has changed during that, as her lawyer indicated.
What is clear, however, is that its vision is severely deterrent.
“I can no longer work. I can no longer drive. I must just be careful walking around my bloc. Buffy said:” I cannot see at night. “I completely changed my life.”
A widow, she hoped to spend her retirement to travel and spend time with her family. Now you are concerned that you are able to take care of themselves.
“I no longer hope to see my grandchildren. I no longer hope to see their faces clearly.” I cannot get any kind of independence – I will not be able to live myself. ”
“All my hopes and my dreams have decreased.”
